- 专利标题： Controlled-release PTH compound
-
申请号： US18063294申请日： 2022-12-08
-
公开(公告)号： US11890326B2公开(公告)日： 2024-02-06
- 发明人: Kennett Sprogøe , Felix Cleemann , Guillaume Maitro , Mathias Krusch , Thomas Wegge , Joachim Zettler
- 申请人： ASCENDIS PHARMA BONE DISEASES A/S
- 申请人地址： DK Hellerup
- 专利权人： ASCENDIS PHARMA BONE DISEASES A/S
- 当前专利权人： ASCENDIS PHARMA BONE DISEASES A/S
- 当前专利权人地址： DK Hellerup
- 代理机构： Alston & Bird LLP
- 优先权： EP 191451 2016.09.29 EP 155843 2017.02.13
- 主分类号： A61K38/29
- IPC分类号： A61K38/29 ; A61K47/60 ; A61K9/00 ; A61K9/16 ; A61K47/54 ; A61K47/34
摘要：
The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.
公开/授权文献
- US20230248836A1 Dosage Regimen for a Controlled-Release PTH Compound 公开/授权日：2023-08-10
信息查询
IPC分类:
